Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
antineoplastic agent |
| gptkbp:approvedBy |
gptkb:FDA
2010 |
| gptkbp:ATCCode |
L01XX41
|
| gptkbp:brand |
gptkb:Halaven
|
| gptkbp:CASNumber |
253128-41-5
|
| gptkbp:category |
antineoplastic agent
microtubule inhibitor |
| gptkbp:chemicalFormula |
C40H59NO11
|
| gptkbp:derivedFrom |
halichondrin B
|
| gptkbp:discoveredBy |
gptkb:Eisai_Co.,_Ltd.
|
| https://www.w3.org/2000/01/rdf-schema#label |
eribulin
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
microtubule dynamics inhibitor
|
| gptkbp:molecularWeight |
729.9 g/mol
|
| gptkbp:PubChem_CID |
CHEMBL1201836
6917909 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
fatigue alopecia neutropenia |
| gptkbp:UNII |
A8Q051P6F7
|
| gptkbp:usedFor |
gptkb:cancer
liposarcoma |
| gptkbp:bfsParent |
gptkb:Halaven
|
| gptkbp:bfsLayer |
7
|